AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Presentation (Timestamp: 3 Months Prior to Admission)
A 27-year-old male software engineer (residing in Delhi NCR, 9-year history of weekly cannabis smoking ,no tobacco use) presents to the emergency department with a 3-month history of subacute progressive cough with white sputum, exertional dyspnea, and sudden onset of severe bilateral chest pain.
HPI:
- 3 Months Ago: Developed an insidious, non-productive cough that gradually became productive of thick white sputum, accompanied by exertional shortness of breath when climbing stairs or walking uphill.
- 2 Days Ago: Experienced abrupt, severe bilateral pleuritic chest pain exacerbated by deep inspiration and leaning forward, forcing him to seek emergency care.
- ROS: Denies fever, chills, night sweats, weight loss, hemoptysis, skin rashes, joint pain, or eye symptoms.
- Social & Exposure History: weekly cannabis smoker (for 9 years). Denies cigarette smoking, illicit IV drug use, or occupational chemical exposures. No prior medical or surgical history.

Resident:

Hello, Chief Resident here.

Key Findings: A 27-year-old male cannabis smoker presenting with a 3-month subacute progressive cough, thick white sputum, and exertional dyspnea, acutely complicated by 2 days of severe bilateral pleuritic chest pain.

Differential Diagnoses:
1. Spontaneous Pneumothorax/Pneumomediastinum 2° to Cannabis-induced Bullous Disease (45%): Deep inhalation/Valsalva maneuvers in cannabis users can cause apical bullae rupture.
2. Pulmonary Infection (Endemic TB / Fungal e.g., Aspergillosis) (30%): Subacute cough/sputum in an endemic region (Delhi NCR); cannabis carries mold exposure risks.
3. Pulmonary Langerhans Cell Histiocytosis (PLCH) (15%): Smoking-related cystic lung disease predisposing to recurrent pneumothoraces.
4. Acute Pericarditis / Pleuropericarditis (10%): Explains acute pleuritic chest pain, though positional exacerbation pattern is atypical.

Recommended Prioritized Tests:
1. Urgent Chest X-ray (Erect PA view): To rule out pneumothorax, pneumomediastinum, or gross consolidation.
2. HRCT Thorax: For precise visualization of cystic/bullous disease, cavitation, or interstitial changes.
3. ECG & Troponin I: To rule out pericarditis or myocardial strain.
4. Sputum Diagnostics: AFB stain, GeneXpert MTB/RIF, and fungal smear/culture.
5. CBC & Inflammatory Markers (CRP/ESR): To evaluate underlying infectious or inflammatory processes.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of CXR/HRCT for bullae/PTX, but underweights cannabis-associated aspergillosis or talcosis; pericarditis ranking inflated without rub/ECG data. Add ABG and quantitative IgE early. Sputum workup incomplete without galactomannan.

Top 3 DDx:
1. Cannabis-induced bullous lung disease with secondary spontaneous pneumothorax/pneumomediastinum
2. Chronic pulmonary aspergillosis (or hypersensitivity pneumonitis) from contaminated cannabis
3. Pulmonary Langerhans cell histiocytosis

Specific points:
1. Obtain upright CXR + lateral immediately; if negative, proceed to HRCT with expiratory views.
2. Add serum galactomannan, total IgE, and Aspergillus-specific IgE/IgG.
3. ABG + full PFTs (once stable) for obstruction/restriction.
4. ECG + bedside echo to definitively exclude pericardial involvement.
5. Quantiferon-TB and induced sputum for AFB/GeneXpert/fungal.
6. Counsel immediate cannabis cessation; screen for concurrent vaping.
7. Consider VATS biopsy if cysts persist post-resolution.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Cannabis-related barotrauma—spontaneous pneumomediastinum (or small pneumothorax) complicating subclinical bullous lung disease. Deep, prolonged inhalation with Valsalva maneuver in chronic cannabis use ruptures subpleural blebs, explaining both the 3-month cough/dyspnea (early bullous/bronchitic change) and the acute pleuritic pain (air leak).

Top differentials and fit:
- Pneumothorax: Fits well, but bilateral simultaneous PTX is rare; pneumomediastinum better explains bilateral pain.
- Pericarditis: Poor fit—pericarditic pain improves leaning forward; this worsens. This is the key pivot favoring pleural/mediastinal, not pericardial, pathology.
- TB/CPA (aspergillosis): Must exclude in Delhi NCR with cannabis mold exposure, but absence of fever, night sweats, weight loss, or hemoptysis lowers pretest probability.
- PLCH: Possible (smoker, cysts, PTX risk), but cannabis-only smoking makes it less likely.

Key pivot: Acute pleuritic pain worse leaning forward—a mechanical air-leak signature, not pericarditis.

Next move: Erect PA + lateral CXR immediately; proceed to HRCT if negative (detects occult pneumomediastinum/bullae); ECG to close out pericarditis.

Teaching pearl: "Worse leaning forward" redirects you from pericardium to pleura/mediastinum—think air, not inflammation.

Round 2

User:

Stage 2: Physical Examination & Initial Emergency Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C, HR 54 bpm, BP 117/67 mmHg, RR 20/min, SpO2 97% on 2L oxygen. Mild respiratory distress. Lungs: Decreased breath sounds bilaterally with hyperresonance on chest percussion. Chest tubes placed bilaterally under wall suction with immediate air evacuation. Skin: No cutaneous fibrofolliculomas, papules, or xanthomas. MSK & Neuro: Unremarkable.
Initial Laboratory Evaluation:
- Hemogram: WBC 8.2 x 10³/µL, Hb 13.4 g/dL, Platelets 251,000/µL.
- Biochemistry: Serum Creatinine 0.9 mg/dL, LFTs normal, electrolytes normal.
- Targeted Serologies & Biomarkers: Alpha-1 Antitrypsin level 100 mg/dL (normal 75–150 mg/dL, ruling out A1AT deficiency), Serum VEGF-D 16.8 pg/mL (normal <96.2 pg/mL, ruling out Lymphangioleiomyomatosis / LAM), Anti-SSA/SSB negative, HIV 1/2 negative, Quantiferon-TB Gold negative.

Resident:

Hello, Chief Resident here.

Updated Key Findings: 27-year-old male cannabis user with simultaneous bilateral spontaneous pneumothoraces requiring chest tube thoracostomies. Excluded: A1AT deficiency, LAM (normal VEGF-D), TB, and HIV.

Differential Diagnoses:
1. Cannabis-Induced Bullous Lung Disease / Barotrauma (50%): Apical bullae rupture from deep inhalation/Valsalva maneuvers; supported by negative A1AT/LAM workup.
2. Pulmonary Langerhans Cell Histiocytosis (25%): Inhaled antigen-driven upper-lobe cystic disease causing pneumothorax.
3. Birt-Hogg-Dubé (BHD) Syndrome (15%): Bilateral pneumothoraces via basal subpleural cysts; up to 50% lack cutaneous lesions.
4. Cannabis-Associated Fungal Infection (e.g., Aspergillosis) (10%): Mold exposure leading to bullous/cavitary structural degradation.

Next Steps:
1. HRCT Thorax (post-re-expansion): Characterize cyst morphology/distribution (apical vs. basal) to differentiate PLCH, BHD, and bullous disease.
2. Fungal Diagnostics: Serum Galactomannan, Total IgE, Aspergillus-specific IgE/IgG, and sputum fungal cultures.
3. FLCN Genetic Testing: If HRCT demonstrates basal/lentiform subpleural cysts.
4. Thoracic Surgery Consultation: Evaluate for surgical intervention (VATS/pleurodesis) given simultaneous bilateral presentation.

Attending:

Hello Attending Consultant here

Critique: Appropriate escalation to bilateral chest tubes and exclusion of A1AT/LAM/TB/HIV. Overweights BHD without basal cyst confirmation; underemphasizes cannabis barotrauma mechanics and need for immediate post-drain imaging. Fungal workup correctly added but incomplete without BAL. Surgery consult timely given bilateral recurrence risk.

Top 3 DDx:
1. Cannabis-induced bullous disease with bilateral secondary spontaneous pneumothoraces
2. Pulmonary Langerhans cell histiocytosis
3. Birt-Hogg-Dubé syndrome (occult)

Specific points:
1. Urgent post-reexpansion HRCT (inspiratory/expiratory) for cyst distribution, bullae, and residual air leaks.
2. Serum galactomannan + Aspergillus IgE/IgG + total IgE; consider BAL fungal/AFB.
3. FLCN sequencing only if HRCT shows basal lentiform cysts.
4. Continuous wall suction; assess for persistent air leak >48–72 h.
5. Early VATS pleurodesis/bullectomy consult given simultaneous bilateral PTX.
6. Serial ABGs + wean O2; full PFTs post-resolution.
7. Mandatory cannabis cessation counseling + urine tox screen.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Cannabis-induced bullous lung disease with bilateral secondary spontaneous pneumothoraces from barotrauma (deep inhalation + Valsalva). The unifying thread is chronic cannabis smoking → apical/subpleural bullae → rupture; Stage 2 confirms bilateral hyperresonance and air evacuation.

Top differentials and fit:
- PLCH: Fits (smoker, cystic disease, PTX), but cannabis-only use and no systemic features make it less likely; HRCT cyst distribution will decide.
- Birt-Hogg-Dubé: Bilateral PTX fits, but no skin lesions and no basal cyst data yet; A1AT and LAM already excluded, so BHD is the main genetic mimic.
- Fungal/cavitary disease: Possible mold exposure via cannabis, but Quantiferon negative, no fever/hemoptysis; still pending galactomannan.

Key pivot: Simultaneous bilateral pneumothoraces in a young non-smoker mandates a cystic/bullous lung disease workup; the negative A1AT/VEGF-D narrows it to cannabis barotrauma, PLCH, or BHD.

Next move: Post-re-expansion HRCT with expiratory views to characterize cyst morphology (apical bullae vs. basal lentiform vs. upper-lobe bizarre cysts), which will directly guide FLCN testing vs. VATS biopsy.

Teaching pearl: Bilateral pneumothorax = think cystic lung disease until proven otherwise; distribution on HRCT is the diagnostic Rosetta Stone.

Round 3

User:

Stage 3: High-Resolution CT Chest Imaging (Timestamp: Hospital Days 1-2)
HRCT Chest Findings:
- Bilateral spontaneous pneumothoraces with intercostal chest drains in situ.
- Widespread, upper- and middle-lobe predominant pulmonary parenchymal destruction featuring numerous bizarre, stellate, multiloculated thin- and thick-walled cysts (4–15 mm).
- Numerous small peribronchiolar pulmonary nodules (2–5 mm) interspersed among the cystic lesions.
- Striking sparing of the costophrenic angles and lung bases.
- No hilar or mediastinal lymphadenopathy.

Resident:

Hello, Chief Resident here.

Updated Key Findings: HRCT demonstrates pathognomonic features of upper/middle-lobe predominant, bizarre stellate cysts (4–15 mm) and peribronchiolar nodules with classic sparing of the lung bases and costophrenic angles, complicated by bilateral pneumothoraces.

Differential Diagnoses:
1. Pulmonary Langerhans Cell Histiocytosis (PLCH) (80%): Pathognomonic radiological triad (nodules, bizarre cysts, upper-lobe predominance with basal sparing) driven by cannabis smoking.
2. Cannabis-Induced Bullous Disease with Barotrauma (10%): Co-existing pathology; however, pure bullous disease does not account for the diffuse peribronchiolar nodules or stellate cyst morphology.
3. Birt-Hogg-Dubé Syndrome (5%): Unlikely given striking basal sparing (BHD typical for basal/medial subpleural cysts).
4. Hypersensitivity Pneumonitis / Cannabis Mold Reaction (5%): Can produce centrilobular nodules, but rare to cause widespread bizarre cysts without systemic symptoms.

Recommended Next Steps:
1. Thoracic Surgery Consult for VATS: Bilateral mechanical pleurodesis and lung wedge resection biopsy for histopathology (CD1a, S100, Langerin/CD207 staining).
2. Bronchoscopy with BAL: Flow cytometry for CD1a+ Langerhans cells (>5% highly specific for PLCH).
3. Strict Smoking/Cannabis Cessation: Primary disease-modifying therapy for PLCH.
4. Full Pulmonary Function Tests with DLCO: Perform baseline evaluation once chest drains are removed.

Attending:

Hello Attending Consultant here

Critique: Excellent HRCT interpretation locking onto classic PLCH morphology; correctly demotes BHD (basal sparing) and pure bullous disease (nodules + stellate cysts). Over-relies on BAL CD1a alone—tissue remains gold standard. VATS timing appropriate given bilateral drains; cessation counseling under-emphasized as disease-modifying.

Top 3 DDx:
1. Pulmonary Langerhans cell histiocytosis (cannabis-driven)
2. Smoking-related interstitial fibrosis with bullae/cysts
3. Multifocal cystic adenocarcinoma (rare mimic)

Specific points:
1. Proceed to VATS wedge biopsy + mechanical pleurodesis bilaterally for definitive CD1a/S100/langerin IHC.
2. Concurrent BAL for CD1a+ cells (>5%) and exclusion of infection.
3. Immediate, verified cannabis cessation—primary therapy; urine tox confirmation.
4. Baseline PFTs + DLCO post-drain removal; serial HRCT at 3–6 mo.
5. Screen for extrapulmonary PLCH (bone, pituitary, skin).
6. Hold systemic steroids/chemotherapy pending biopsy confirmation of progressive disease.
7. Genetic counseling unnecessary given imaging.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Pulmonary Langerhans Cell Histiocytosis (PLCH) presenting as bilateral secondary spontaneous pneumothoraces in a chronic cannabis smoker. HRCT is near-pathognomonic: bizarre stellate cysts + peribronchiolar nodules, upper/mid-lobe predominant with basal/costophrenic sparing. Cannabis is the antigenic driver.

Top differentials and fit:
- Cannabis-induced bullous disease: Coexists but cannot explain peribronchiolar nodules or stellate cyst morphology; bullae are smooth, apical, and lack nodular interstitial change.
- Birt-Hogg-Dubé: Poor fit—BHD cysts are basal, subpleural, lentiform; this case shows basal sparing.
- LIP / cystic HP: Rare, no systemic features, no basal predominance; nodule-cyst combination favors PLCH.

Key pivot: The peribronchiolar nodules interspersed with bizarre stellate cysts and basal sparing distinguish PLCH from simple bullous emphysema or BHD—this radiologic signature is the decisive discriminator.

Next move: VATS wedge biopsy with CD1a/S100/langerin IHC for definitive confirmation, performed alongside mechanical pleurodesis to prevent recurrence.

Teaching pearl: In a young smoker with bilateral pneumothorax and upper-lobe stellate cysts + nodules, PLCH is the diagnosis until biopsy proves otherwise—cannabis counts as smoking.

Round 4

User:

Stage 4: Surgical Lung Biopsy & Histopathologic Diagnostic Confirmation (Timestamp: Hospital Days 3-5)
Diagnostic Interventions & Histopathology:
- Procedure: Video-Assisted Thoracoscopic Surgery (VATS) wedge biopsy of the right upper lobe.
- Microscopy: Peribronchiolar stellate granulomatous lesions composed of abundant pale histiocytic cells with characteristic grooved ("coffee-bean") nuclei.
- Immunohistochemistry: Strong, diffuse positivity for CD1a, Langerin (CD207), and S100.
- Co-Existing Pathology: Surrounding lung parenchyma shows pigment-laden intra-alveolar macrophages consistent with cannabis/smoking-related Respiratory Bronchiolitis (RB).

Resident:

Hello, Chief Resident here.

Updated Key Findings: VATS lung biopsy provides definitive diagnostic confirmation of Pulmonary Langerhans Cell Histiocytosis (PLCH), demonstrating peribronchiolar lesions with grooved "coffee-bean" histiocytes strongly positive for CD1a, Langerin (CD207), and S100, alongside co-existing smoking-related Respiratory Bronchiolitis.

Diagnoses:
1. Pulmonary Langerhans Cell Histiocytosis (PLCH) (95%): Biopsy-proven, gold-standard confirmation driven by chronic cannabis smoke exposure.
2. Respiratory Bronchiolitis (5%): Histologically confirmed co-existing parenchymal response to inhaled cannabis smoke.

Next Steps & Management Plan:
1. Strict Cannabis & Smoking Cessation: Primary disease-modifying therapy; cessation alone induces stabilization or partial regression in up to 50–75% of PLCH cases.
2. Bilateral Pleurodesis: Ensure surgical pleurodesis was performed during VATS given the high rate of pneumothorax recurrence.
3. Baseline Functional Assessment: Complete PFTs with DLCO post-recovery to establish baseline pulmonary impairment.
4. Extrapulmonary Screening: Screen for bone pain and diabetes insipidus (polyuria/polydipsia) to rule out systemic disease.
5. Surveillance: Serial HRCT and PFTs at 3–6 months. Reserve systemic corticosteroids or cladribine for progressive disease despite cessation.

Attending:

Hello Attending Consultant here

Critique: Biopsy confirmation of PLCH is definitive and plan correctly prioritizes cessation as disease-modifying. Under-emphasizes immediate post-VATS air-leak management and BRAF/MAPK testing for progressive cases. Extrapulmonary screen incomplete without MRI pituitary/bone scan; RB co-pathology warrants concurrent emphysema monitoring.

Top 3 DDx:
1. Pulmonary Langerhans cell histiocytosis (biopsy-proven, cannabis-driven)
2. PLCH with coexistent respiratory bronchiolitis-ILD
3. Smoking-related interstitial fibrosis (minor contributor)

Specific points:
1. Confirm bilateral mechanical pleurodesis completed; monitor for persistent air leak.
2. Enforce verified cannabis cessation (urine tox + counseling); sole first-line therapy.
3. Full PFTs + DLCO + 6MWT at drain removal; repeat q3mo.
4. Screen extrapulmonary sites: MRI brain/pituitary, skeletal survey, urine osmolality.
5. Molecular testing (BRAF V600E) on tissue if progression despite cessation.
6. Serial HRCT at 3–6 mo; reserve cladribine/steroids for declining DLCO/FVC.
7. Lifelong pneumothorax recurrence counseling + activity restriction.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Biopsy-proven Pulmonary Langerhans Cell Histiocytosis (PLCH), driven by chronic cannabis smoking, presenting as bilateral secondary spontaneous pneumothoraces with co-existing respiratory bronchiolitis. CD1a/Langerin/S100 positivity and stellate peribronchiolar granulomas are the gold standard.

Top differentials and fit:
- Cannabis-induced bullous disease: Coexists (RB/pigmented macrophages) but cannot produce Langerhans cell granulomas; now a secondary process.
- Birt-Hogg-Dubé: Excluded by basal sparing, no FLCN phenotype, and biopsy.
- Disseminated LCH: Must screen (bone, pituitary), but isolated pulmonary disease is typical in adult smokers.

Key pivot: Histopathology confirming Langerin/CD1a+ grooved histiocytes closes the case—radiologic suspicion becomes definitive PLCH, and cannabis is identified as the antigenic driver.

Next move: Enforce verified cannabis cessation (the only disease-modifying therapy), confirm bilateral pleurodesis completed, and initiate structured surveillance (PFTs/DLCO + HRCT at 3–6 months) with BRAF testing reserved for progression.

Teaching pearl: PLCH is a smoking-related clonal myeloid disorder, not just interstitial lung disease—smoking cessation is treatment, not merely prevention.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Pulmonary Langerhans Cell Histiocytosis (PLCH) complicated by bilateral secondary spontaneous pneumothorax in a young cannabis smoker.
Treatment Plan:
- Management of Pneumothorax: Bilateral chest tube thoracostomy and chemical pleurodesis.
- Primary Intervention: Complete, mandatory cessation of all inhalational cannabis and smoking products. Avoidance of empiric corticosteroids (ineffective for non-inflammatory cystic PLCH).
- Outcome: Complete lung re-expansion, successful chest tube removal, and stable pulmonary function testing (PFTs) at 6-month follow-up following sustained smoking cessation.

Resident:

Hello, Chief Resident here.

Key Findings: 27-year-old male cannabis smoker with biopsy-proven Pulmonary Langerhans Cell Histiocytosis (PLCH) presenting with bilateral spontaneous pneumothoraces, successfully managed with bilateral pleurodesis and complete cannabis cessation, resulting in full re-expansion and stable 6-month PFTs.

Final Diagnoses:
1. Pulmonary Langerhans Cell Histiocytosis (PLCH) (100%): Biopsy-confirmed (CD1a+, Langerin+, S100+), classic HRCT stellate cysts/nodules with basal sparing, driven by cannabis smoking.

Long-Term Management & Surveillance:
1. Sustained Abstinence: Mandatory, complete cessation of all cannabis, tobacco, and vaping; monitor with periodic urine toxicology screens.
2. Routine Surveillance: Serial PFTs with DLCO and HRCT every 6–12 months to monitor for disease progression or recurrence.
3. Molecular Contingency: Preserve tissue for BRAF V600E mutation testing; reserve systemic therapy (cladribine or targeted BRAF inhibitors) for progressive decline despite smoking cessation.
4. Extrapulmonary Vigilance: Screen for skeletal pain or polyuria/polydipsia (central diabetes insipidus).
5. Activity Precautions: Counsel on permanent avoidance of SCUBA diving and aggressive deep inhalation/Valsalva maneuvers.

Attending:

Hello Attending Consultant here

Critique: Plan correctly centers verified cessation as disease-modifying and avoids futile steroids. Under-specifies molecular profiling timing and extrapulmonary imaging; chemical (vs mechanical) pleurodesis alone carries higher recurrence risk in PLCH cysts. 6-month stability is encouraging but incomplete without DLCO trajectory and BRAF status.

Top 3 DDx:
1. Pulmonary Langerhans cell histiocytosis (biopsy-proven, cannabis-driven)
2. PLCH + residual respiratory bronchiolitis-ILD
3. Smoking-related cystic emphysema (minor co-factor)

Specific points:
1. Confirm mechanical (not solely chemical) pleurodesis bilaterally; document air-leak resolution.
2. Enforce lifelong cannabis/tobacco abstinence with serial urine tox + counseling.
3. PFTs/DLCO + 6MWT q3–6 mo; HRCT at 6 then 12 mo.
4. BRAF V600E testing on archived tissue now for future targeted options.
5. Extrapulmonary screen: MRI pituitary, skeletal survey, urine osmolality.
6. Permanent activity restriction (no diving/Valsalva); pneumothorax recurrence education.
7. Escalate to cladribine/MEK inhibitor only if FVC/DLCO declines >10–15%.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Biopsy-proven Pulmonary Langerhans Cell Histiocytosis (PLCH) with bilateral secondary spontaneous pneumothoraces, now stabilized after pleurodesis and verified cannabis cessation. This is a cannabis-driven clonal myeloid disease of the lung.

Top differentials and fit:
- Cannabis bullous disease: Coexists histologically (respiratory bronchiolitis) but is not the primary cyst-forming process.
- Birt-Hogg-Dubé / LAM: Excluded by basal sparing, negative VEGF-D, and Langerin+ histology.
- Disseminated LCH: Still requires periodic extrapulmonary surveillance, but adult-onset isolated pulmonary PLCH in a smoker is typical.

Key pivot: Smoking cessation is the disease-modifying treatment—steroids are ineffective in non-inflammatory cystic PLCH; only ~50–75% stabilize or regress with abstinence alone.

Next move: Long-term structured surveillance (PFTs/DLCO + HRCT q6–12 months), archived BRAF V600E testing for future targeted therapy, and permanent activity restrictions (no SCUBA, Valsalva).

Teaching pearl: PLCH is treated by removing the antigen, not suppressing the immune system—smoking cessation is chemotherapy here.

Top 15 Takeaways for Clinicians

  1. Definition of Pulmonary Langerhans Cell Histiocytosis (PLCH): PLCH is a rare, smoking-related clonal myeloid/dendritic cell proliferation characterized by peribronchiolar histiocytic granulomas leading to destruction of lung parenchyma and cystic airway remodeling.
  2. Inhalational Antigenic Drivers: Over 90% of PLCH cases occur in young adults with a history of cigarette smoking or heavy daily inhalational cannabis use (water pipes/bongs and joints).
  3. Complication of Spontaneous Pneumothorax: Secondary spontaneous pneumothorax occurs in 15–20% of PLCH patients due to subpleural cyst or bleb rupture, and can present as simultaneous bilateral pneumothoraces.
  4. Diagnostic HRCT Constellation: High-resolution CT (HRCT) chest characteristically reveals small peribronchiolar nodules (2–5 mm) interspersed with bizarre, stellate, multiloculated thin- and thick-walled cysts (4–15 mm).
  5. Pathognomonic HRCT Distribution: PLCH features a striking upper- and middle-lobe predominance with strict sparing of the costophrenic angles and lung bases, distinguishing it from Birt-Hogg-Dubé syndrome and emphysema.
  6. Exclusion of Lymphangioleiomyomatosis (LAM): Normal serum Vascular Endothelial Growth Factor-D (VEGF-D <96.2 pg/mL) excludes LAM, which typically causes diffuse, round, uniform cysts without basal sparing in females.
  7. Exclusion of Alpha-1 Antitrypsin (A1AT) Deficiency: Normal serum Alpha-1 Antitrypsin levels (75–150 mg/dL) rule out A1AT deficiency, which produces panacinar emphysema predominantly involving the lung bases.
  8. Gold Standard Histopathology: Surgical VATS wedge biopsy confirms PLCH by demonstrating peribronchiolar stellate granulomatous infiltrates composed of pathogenic Langerhans cells with characteristic grooved ("coffee-bean") nuclei.
  9. Immunohistochemical Markers: Pathogenic Langerhans cells demonstrate strong, diffuse immunohistochemical positivity for CD1a, Langerin (CD207), and S100.
  10. Co-Existing Respiratory Bronchiolitis (RB): Lung biopsies in PLCH frequently demonstrate co-existing Respiratory Bronchiolitis, characterized by accumulation of pigment-laden intra-alveolar macrophages in adjacent airways.
  11. Smoking/Cannabis Cessation as Disease-Modifying Therapy: Complete, mandatory cessation of all inhalational tobacco and cannabis products is the primary disease-modifying intervention, inducing disease stabilization or regression in 50–75% of patients.
  12. Inadequacy of Corticosteroid Monotherapy: Systemic corticosteroids are ineffective for isolated, non-inflammatory cystic PLCH and should be avoided in the absence of severe inflammatory cellular nodular progression.
  13. Role of BRAF V600E Molecular Testing: Up to 50% of PLCH cases harbor somatic BRAF V600E mutations; molecular testing on archived tissue guides targeted therapy (such as Vemurafenib or Dabrafenib) in refractory disease.
  14. Systemic Extrapulmonary Screening: Adult-onset PLCH requires screening for extrapulmonary involvement, including skeletal survey/MRI for painful bone lesions and pituitary evaluation for central diabetes insipidus.
  15. Surgical Pleurodesis & Long-Term Surveillance: Following VATS wedge biopsy and pneumothorax evacuation, mechanical or chemical pleurodesis is essential to prevent recurrence, complemented by serial PFTs/DLCO every 6–12 months.